Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scientific Inc. reports developments tied to computerized drug delivery instruments for dental and medical applications. The company’s Dynamic Pressure Sensing technology supports pressure-guided injection and fluid-aspiration procedures, including dental anesthesia delivery through The Wand STA system and medical applications such as CompuFlo for controlled epidural injections.
Recurring news themes include financial results, business-update calls, commercialization programs, physician and dental-practice adoption, distributor and reimbursement infrastructure, international product registrations, disposable utilization, operating expense initiatives, and capital actions involving common stock and warrants.
Milestone Scientific (NYSE American: MLSS) reported growing clinical adoption and physician acceptance of its CompuFlo Epidural System, supported by a new University of Texas Medical Branch study in Operative Neurosurgery.
The study found CompuFlo-guided spinal cord stimulator implantation was associated with a 91% reduction in odds of composite complications versus traditional loss-of-resistance techniques.
Milestone Scientific (NYSE:MLSS) reported Q1 2026 revenue of $2.16 million, slightly below $2.23 million in Q1 2025. Gross profit was $1.56 million with a 72.3% margin. Operating loss improved to $828,000 from $2.0 million as operating expenses fell over 30%.
Net loss was $840,000 ($0.01 per share). Medical segment revenue more than doubled year-over-year. As of March 31, 2026, cash was $1.2 million. A subsequent private placement raised $2.15 million. Management reaffirmed 2026 revenue guidance of $9.8–$10.2 million and continues to target cash flow breakeven in early 2027, while substantial doubt about going concern status remains.
Milestone Scientific (NYSE: MLSS) will host a conference call at 8:30 AM ET on May 14, 2026 to discuss first-quarter 2026 financial results, corporate progress, and other developments. Dial-in numbers, access codes, a live webcast and replay are provided; the audio replay is available through May 28, 2026.
Webcast: https://www.webcaster5.com/Webcast/Page/2306/53997. U.S. dial-in: 888-506-0062; international: +1 973-528-0011; access code: 950491. Replay dial-in access code: 53997.
Milestone Scientific (NYSE: MLSS) reported expansion of its CompuFlo® medical business, launching an Advisor Program in February 2026 and initiating procedural use across multiple Medicare Administrative Contractor jurisdictions and select commercial payers.
The program is active in NJ, FL, PA, NY, TN, TX, and GA, with Noridian and NGS expansion underway. Milestone reports active epidural procedures, initial case submissions to payers, growing sales consultant coverage, and academic collaborations. CompuFlo® retains CPT Category III code 0777T; Category I progression is not assured.
Milestone Scientific (NYSE:MLSS) closed a $2.15 million private placement of common stock and warrants on April 20, 2026, with an additional $2.69 million available if cash warrants are fully exercised. The company sold 7,962,963 units at $0.27 per unit; each unit includes one share and one warrant exercisable at 125% of the unit price.
Proceeds comprised approximately $1.80 million cash and $351,000 from conversion of 2025 convertible bridge notes. Directors and officers, including the CEO and chairman, participated for an aggregate $150,000 cash purchase. The placement closed April 20, 2026, under NYSE American rules.
Milestone Scientific (NYSE: MLSS) reported 2025 results and a 2026 outlook, highlighting a transition from restructuring to growth. Full-year revenue was $9.0M (2024: $8.6M); gross profit unchanged at $6.4M. Operating loss improved to $5.7M from $6.8M; net loss was $5.7M or $(0.07) per share. Cash totaled $1.1M, working capital $3.3M, and convertible debt $800,000.
Management expects 2026 revenue of $9.8M–$10.2M with double-digit growth and forecasts CompuFlo sales of $0.5M–$0.6M (~400% growth). Company reiterated focus on disciplined spending, commercial expansion, and target of cash flow breakeven in early 2027.
Milestone Scientific (NYSE: MLSS) will hold a conference call at 8:30 AM ET on Wednesday, April 1, 2026 to discuss fourth quarter and full‑year 2025 financial results and corporate developments. The call includes a live webcast, telephone access, and an audio replay through April 15, 2026.
Telephone access codes and the webcast URL are provided for investors and analysts to listen live or via replay.
Milestone Scientific (NYSE: MLSS) launched the CompuFlo Advisor Program on February 1, 2026 to accelerate commercial adoption, increase recurring disposable revenue, and generate clinical data aimed at improving Medicare reimbursement for CPT 0777T.
The program targets high-volume interventional pain and anesthesia practices in select MAC jurisdictions (Novitas, First Coast, Noridian, Palmetto) with a planned 1,000–2,000 case submissions in the initial six months and a commercial infrastructure intended to support phased national expansion.
Milestone Scientific (NYSE: MLSS) launched The Wand Ambassador Program to expand peer-to-peer clinical engagement and accelerate adoption of The Wand STA (Single Tooth Anesthesia) System in dentistry.
The pilot started on Dec 8, 2025 with six registered dental professionals and reported early positive feedback and inbound interest. Milestone plans to scale to approximately 250 ambassadors over 12 months, supported by onboarding, centralized learning resources, and tools that track engagement.
Management expects the program, plus expanded social media outreach, to drive ~2–3x growth in product demonstrations and improve demo-to-sales conversion efficiency while remaining capital-efficient.
Milestone Scientific (NYSE: MLSS) reported third-quarter results for the period ended September 30, 2025, highlighting cost reductions and stable revenue.
Key Q3 figures: revenue ~$2.4M (vs $2.5M), gross profit ~$1.6M (70% of revenue), operating loss $(1.1)M (improved ~23% YoY), and net loss $(1.2)M, $(0.01) per share. Nine-month revenue was ~$6.9M (+5% YoY) with a nine-month net loss of $(4.6)M, $(0.06) per share. The company said it reduced operating expenses by over $500,000 in Q3 and reported cash and cash equivalents ~$1.3M and working capital ~$3.1M. Management emphasized operational transformation, international dental growth, and increasing medical disposables recurring revenue.